Article published on therapeutic innovations in hemophilia

Article published on therapeutic innovations in hemophilia

Major treatment advances have been made in the treatment of hemophilia in the last several decades, including recent biotechnology breakthroughs. Global advocacy and industry investment have led to ever more effective therapies—but sustaining this progress requires ongoing commitment as funding and innovation face new threats.

Also available in: Français Español

A new article in Blood Advances, “Therapeutic Innovations in Hemophilia: The Essential Role of a Positive Reinvestment Cycle”—written by World Federation of Hemophilia (WFH) Vice President, Medical, Glenn Pierce, MD, PhD, and WFH Medical Member Cedric Hermans, MD—highlights these issues and recommends a path forward.

Hemophilia stands out among rare genetic diseases for its significant therapeutic advancements, closely tied to substantial financial investments. Key factors driving this progress include severe hemorrhagic consequences from an early age, its impact on royal families, the HIV and hepatitis C contamination tragedies, the identification of FVIII and FIX genes, and advancements in biotechnology. Maintaining low, measurable concentrations of FVIII or FIX in the blood has proven pivotal in improving patient outcomes. With reinvestments from biopharmaceutical partners, revolutionary options, including gene therapy, have emerged. However, this cycle of innovation and investment, essential for curing all patients worldwide, faces potential threats. Equally essential is expanding access and revenue by turning low-income countries into viable markets.

“Therapeutic Innovations in Hemophilia: The Essential Role of a Positive Reinvestment Cycle” aims to highlight the critical importance of investing in hemophilia treatment and research, a topic of concern for all stakeholders within the hemophilia community. To read the full article in Blood Advances, click here.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.